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Abstract
Macrophage (mac)-tropic human immnunodeficiency virus type 1 (HIV-1) and simian immnunodeficiency virus (SIV) in 
brain are associated with neurological disease. Mac-tropic HIV-1 evolves enhanced CD4 interactions that enable macrophage 
infection via CD4, which is in low abundance. In contrast, mac-tropic SIV is associated with CD4-independent infection via 
direct CCR5 binding. Recently, mac-tropic simian-human immunodeficiency virus (SHIV) from macaque brain was also 
reported to infect cells via CCR5 without CD4. Since SHIV envelope proteins (Envs) are derived from HIV-1, we tested 
more than 100 HIV-1 clade B Envs for infection of CD4-negative,  CCR5+ Cf2Th/CCR5 cells. However, no infection was 
detected. Our data suggest that there are differences in the evolution of mac-tropism in SIV and SHIV compared to HIV-1 
clade B due to enhanced interactions with CCR5 and CD4, respectively.
Introduction
HIV-1, HIV-2 and SIV each infect brain tissue and can cause 
neurological complications including encephalopathy and 
dementia [6, 36, 59]. Overall, about 7% of untreated HIV-1+ 
patients (30% of AIDS patients) suffer from severe HIV-
associated dementia (HAD) [6, 22]. Since the introduction 
of combination antiretroviral therapy, HAD and other neu-
rocognitive complications in HIV-1+ subjects have been 
greatly reduced, with only 1% of patients suffering from 
HAD [6].
HIV-1 colonizes the brain during the acute stage of infec-
tion [11]. However, proviral DNA is difficult to detect in 
brain tissue during the asymptomatic phase [3, 12, 34]. 
Perivascular macrophages are the main cell target for HIV-1 
in the brain [16, 17, 19, 22, 29, 52, 60], with resident micro-
glia (macrophage lineage) also becoming infected [9, 16, 
17]. Some studies have indicated that astrocytes that do not 
express CD4 can also be infected [1, 7, 44, 52], particularly 
in pediatric cases [47, 50, 56].
HIV-1 infection of cells is driven by interaction of the 
envelope glycoprotein (Env) with the CD4 receptor and a 
coreceptor, usually CCR5 [58]. The vast majority of HIV-1 
variants outside the central nervous system do not effi-
ciently infect macrophages and replicate in  CD4+ T cells. 
These CCR5-using variants have been termed “R5 non-
macrophage-tropic” [40] or “R5 T-cell tropic” [23, 49]. 
Colonization of the brain by HIV-1 requires the emergence 
of R5 macrophage (mac)-tropic variants that efficiently 
infect macrophages or microglia present there [24, 39, 40] 
and are almost universally found in brain tissue of patients 
with severe neurological complications. These variants are 
adapted to exploit the substantially lower levels of CD4 on 
the surface of macrophages compared to T cells [15, 27, 
41, 43] and interact with CD4 via a high affinity Env:CD4 
interaction [43].
Several SIV/macaque animal models of neuropathogen-
esis have been developed [59], and a number of SIV vari-
ants from brain tissue of these models have been described 
[59]. Similar to HIV-1, these variants from brain tissue are 
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highly mac-tropic [18, 61]. Such SIV variants are, however, 
frequently CD4-independent and are able to infect CD4-neg-
ative cell lines via a direct interaction with the CCR5 core-
ceptor [42]. Moreover, a more recent study of simian-human 
immunodeficiency virus (SHIV) infection of macaques also 
described the presence of CD4-independent Env variants 
present in brain tissue [62]. These models of neurological 
disease often require immune suppression/modulation as 
well as adaptation to use macaque CD4 [4, 59, 62]. Since 
SHIVs carry env genes derived from HIV-1, this observa-
tion suggested that CD4 independence may be a general or 
frequent property of HIV/SIV Envs and variants present in 
brain tissue.
Previously, in our early studies using relatively limited 
numbers of mac-tropic HIV-1 Envs from brain tissue, we 
did not identify any HIV-1 Envs with the capacity to infect 
 CCR5+ cells in the absence of CD4 [39]. Here, we have 
tested a large number of HIV-1 subtype B Envs derived by 
single-genome PCR from brain and other tissues of subjects 
with and without neuroAIDS. We have also investigated 
variation in Env:CCR5 interactions that might indicate an 
adaptation for enhanced Env:CCR5 interactions required for 
CD4 independence.
Materials and methods
Patient tissue samples
Envelope genes were derived from the patients listed in 
Table 1. Full patient details have been published previously 
[21].
Cell cultures
Env+ pseudovirions were prepared in 293T cells by transfec-
tion. HeLa TZM-bl cells [57] were used to estimate  Env+ 
pseudovirion infectivity titers. HeLa TZM-bl cells express 
high levels of CD4, CCR5 and CXCR4 and contain HIV-
inducible β-galactosidase and luciferase reporter genes. 
Canine thymus epithelial cells expressing human CCR5 
(Cf2Th/CCR5 cells) were used to evaluate HIV-1 and SHIV 
CD4-independent infection via CCR5 [62]. 293T cells, 
TZM-bl cells, and Cf2Th/CCR5 cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco-Inv-
itrogen, Carlsbad, CA) supplemented with 5% fetal bovine 
serum (FBS).
Macrophage cultures were prepared from blood mono-
cytes by adherence using buffy coats provided by New York 
Biologics Inv. as described previously [13, 14, 39]. Mono-
cytes were cultured for 5 days in DMEM medium contain-
ing 10% AB+ male human serum (HS) for differentiation 
before setting up for infection. On the day prior to infection, 
the macrophages were washed and resuspended in DMEM 
Table 1  HIV-1+ patients 
investigated
a Bracketed values represent the number of days before death that assessments or measurements were made
b Diagnosis made from patient information after death
c nd no data
d UMMS, University of Massachusetts Medical School
e Normal neurocognitive diagnoses
Patient no. Brain bank or origin Neurological disease  statusa Years of 
infection
CD4 count Viral load
Cells/mm3 Plasma
CA110 UCSD NeuroAIDS (0)b 21 21 (60) 198,957 (60)
7766 Texas NeuroAIDS (0)b 12 43 (21) 1,843 (20)
6568 Texas NeuroAIDS (163) 17 77 (79) >750,000 (402)
10017 Mt. Sinai NeuroAIDS (191) 9 7 (319) 389,120 (381)
NA20 Edinburgh NeuroAIDS ndc 4 nd
NA420 Edinburgh NeuroAIDS nd 12 nd
JR UCLA NeuroAIDS nd nd nd
P1114 UMMSd NeuroAIDS nd 46 nd
CE161 UCSD Normale (192) 13 11 (192) 246,000 (192)
8276 Texas Normal (146) 6 3 (182) 750,000 (184)
6771 Texas Normal (310) 10 23 (354) 75,000 (37)
5057 UCLA Normal (253) 12 663 (148) 29,282 (-1)
6052 UCLA Normal (24) 14 13 (24) 75,000 (24)
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containing 10% HS and cultured in 48-well tissue culture 
plates (1.25×105 cells/well; 0.5 ml/well).
Env+ pseudotype assays
Env+ pseudovirions were produced as described previously 
[39]. Briefly, pseudoviruses were prepared by cotransfec-
tion of 293T cells with  env+ pTOPOenv vector and an env-
minus pNL4.3Δenv using a calcium phosphate transfection 
kit (Profection; Promega Inc.). Cell-free supernatants were 
harvested after culturing for 48 h, and aliquots were frozen 
at -152 °C prior to analysis.
Env+ pseudovirions were titrated on HeLa TZM-bl 
cells, Cf2Th/CCR5 cells, and primary macrophages [39]. 
For HeLa TZM-bl and Cf2Th/CCR5 cells, 2×104 cells in 
0.5 ml were added to each well of 48 well plates the day 
prior to virus titration. One hundred µl of serially diluted 
viral supernatants in DMEM medium containing 5% FBS 
was added to the cells, which were then incubated for 3 h. 
Then, 0.4 ml of DMEM containing 5% FBS was added and 
the cultures were incubated for 48 h. (Hela TZM-bl) or 72 h. 
(Cf2Th/CCR5). TZM-bl cells were fixed in 0.5% gluteral-
dehyde in PBS and stained for β-galactosidase expression 
using X-gal substrate (0.5 mg of X-gal per ml, 3 mM potas-
sium ferricyanide, 3 mM potassium ferrocyanide, 1 mM 
magnesium chloride). Cf2Th/CCR5 cells were fixed in cold 
methanol:acetone (1:1), washed, and immunostained for p24 
using monoclonal antibodies 38:96 K and EF7 (UK Cen-
tre for AIDS Research), followed by an anti-mouse IgG-β-
galactosidase conjugate and X-gal substrate [39].
Macrophages were seeded in 48-well plates and pre-
treated with 0.1 ml of DEAE dextran (10 µg/ml) in DMEM 
medium containing 10% HS for 30 min at 37 °C. The virus 
supernatants were then added, and the plates inoculated by 
spinoculation for 45 minutes in a benchtop centrifuge [38]. 
Infected macrophages were incubated for a further 3 h at 
37 °C before the addition of 0.4 ml of DMEM (10%  AB+ 
male HS) and incubation at 37 °C for seven days. Mac-
rophages were then fixed and immunostained for p24 as 
described for Cf2Th/CCR5 cells. DEAE dextran and spi-
noculation enhance virus infectivity by up to 20-fold by 
increasing attachment [38] and entry [26]. Infection follow-
ing this procedure helps to maximize macrophage infection 
and allows the most mac-tropic  Env+ pseudoviruses to be 
distinguished. It does not bypass the requirement of CD4 
and CCR5 for infection, and the system remains sensitive 
to entry inhibitors, including maraviroc (not shown).  Env+ 
pseudovirion titers were expressed as focus-forming units 
(FFU) estimated by counting individual or small groups of 
blue-stained infected cells by light microscopy.
All titration values for Cf2Th/CCR5 cells, HeLa TZM-
bl cells, and macrophages represent averages of at least 
two independent experiments, each done in duplicate. In 
addition, the macrophage experiments were repeated using 
cells from different donors. Error bars in figures were calcu-
lated from replicate wells of both experiments.
Soluble gp120 production and gp120:CCR5 binding 
assays
Soluble gp120 was produced in 293F cells. 1 ×  106 cells/ml 
in 500 ml were transfected with 250 μg DNA of pJW4303 
containing different gp120s [31] using a suspension of 
293Fectin (Invitrogen Inc.) following the manufacturer’s 
instructions. Transfected cells were cultured in Freestyle 293 
Expression Medium (Invitrogen Inc.) in shaking flasks for 
72 hours. Cells were then pelleted by centrifugation, super-
natants were harvested, gp120 was purified using a lectin 
column. Then, gp120s were concentrated using 50 K-MW-
cutoff centrifugal filter concentrators (Millipore Inc.).
Soluble gp120 binding to CCR5 on the surface of Cf2Th/
CCR5 cells was measured by flow cytometry. Cf2Th/CCR5 
cells were first detached from culture plates using versene. 
One μg of gp120 in 100 μl of PBS containing 1% FBS was 
incubated at room temperature for 30 minutes in the absence 
or presence of 0.5 μg of sCD4 in 96-well V-bottom plates. 
One hundred μl containing 5 ×  106 Cf2Th/CCR5 cells was 
then added, and the plates were incubated for 60 min at 
room temperature. Cells were washed with PBS containing 
1% FBS, and attached gp120 was detected by treating with 
 HIV+ serum mix (1:2500) and incubation for 30 minutes 
at 4 °C before washing again and treating with anti-human 
IgG-FITC conjugate (Southern Biotech Inc.) at 4 °C for 30 
min. Cells were then washed again in PBS plus 1% FBS, fol-
lowed by PBS alone, and were fixed in 4% formaldehyde in 
PBS. Fixed cells from each well were then filtered through a 
35-μm filter capped tube (Falcon Inc.) and analyzed by flow 
cytometry at the UMASS Medical School Flow Cytometry 
Core Lab using a BD LSRII cytometer and DIVA 8.0 acqui-
sition software. Flow analysis was performed using Flowjo, 
10.1r7. Appropriate instrument, assay and analysis controls 
were included in all runs.
Phylogenetic analysis
Phylogenetic and molecular evolutionary analysis was con-
ducted using MEGA, version 7 [53]. Maximum-likelihood 
phylogenetic trees were generated using the general time-
reversible model with gamma distribution. Bootstrap analy-
sis with 1,000 replicates was used to assess the robustness 
of the tree. Significant (≥70%) bootstrap values are shown 
at internal tree nodes. Reference nucleotide sequences 
representing four HIV-1 group M subtype B (http://www.
hiv.lanl.gov/) envelope proteins (FR.83.HXBc2.K03455, 
TH.90.BK132.AY173951, US.98.1058_11.AY331295, and 
NL.00.671_00T36.AY423387) as well as SHIV mac-tropic 
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envelope proteins (AD8.JN560961.1, and SF162P3_
MC_2011.3.JQ672558.1) were used as outgroups.
Statistics
Differences between CD4-independent infection mediated 
by HIV-1 and SHIV Envs were evaluated using non-par-
ametric Mann-Whitney tests. Binding of mac-tropic and 
non-mac-tropic HIV-1 gp120s to CCR5 was compared using 
Wilcoxon matched pairs tests. Finally, significant inhibition 
of HIV-1 gp120:CCR5 binding using maraviroc was tested 
using unpaired t-tests.
Results
No detection of CD4‑independent infection by HIV‑1 
Envs in brain and immune tissue of AIDS patients
Previously, we tested whether pseudoviruses carrying 14 
Envs derived from five subjects with neurological disease 
infected cells expressing CCR5 but not CD4. This relatively 
small panel of Envs included eight highly mac-tropic Envs 
from brain tissue. In that earlier study, none of the  Env+ 
pseudoviruses were able to infect cells in the absence of 
CD4 [39]. Here, we extended our study to more than 100 
further Envs derived from brain or immune tissue of four 
neuroAIDS patients and five AIDS patients without or with 
only minor neurological complications (Table 1) [20, 21]. 
The canine thymus epithelial CF2Th cells expressing human 
CCR5 (Cf2Th/CCR5) were used to test CD4-independent 
infection since these cells were used by Zhuang et al. [62] 
to assess infection in the absence of CD4 by SHIV  Env+ 
pseudoviruses. Control pseudoviruses included those carry-
ing VSV G protein and SHIV Envs #3 and #7, which were 
reported to be CD4 independent by Zhuang et al. [62].
Fig. 1A shows that none of the HIV-1 Envs from neu-
roAIDS tissues conferred significant infection of Cf2Th/
CCR5 cells. In this experiment, we included highly mac-
tropic Envs from frontal lobe tissue (designated FL) of four 
neuroAIDS patients as well as several Envs from lymph 
node (LN) and spleen (SP) that we had previously shown 
to mediate low, modest or high mac-tropism [20]. Here, 
all of these Envs mediated substantial levels of infectivity 
for HeLa TZM-bl cells, while high levels of macrophage 
infection were recorded for all pseudoviruses carrying Envs 
derived from brain tissue and several rare examples of mac-
tropic Envs from lymph node and spleen, as expected. We 
also tested pseudoviruses carrying three SHIV Envs (#3, #7 
and #9) described by Zhuang et al. study [62]. These SHIV 
Envs confer high, medium, and modest infection of Cf2Th/
CCR5 cells, respectively (Fig. 1A, right-hand bars), con-
firming the previous data. The infectivity data presented in 
Fig. 1A, middle panel, also confirm that these brain-derived 
SHIV Envs are mac-tropic.
We also tested pseudoviruses carrying HIV-1 Envs from 
subjects without or with only minor neurological compli-
cations for infection of CD4-negative Cf2Th/CCR5 cells. 
Three of these Envs were from the frontal lobe of subject 
CE161 (one of which, Env FL37-2-6, was a highly mac-
tropic Env), and the remainder were from spleen tissue. No 
significant infection of Cf2Th/CCR5 cells was detected for 
any of the  Env+ pseudovirus tested despite high levels of 
infectivity detected for HeLa TZM-bl cells (Fig. 1B).
Together, these data show that HIV-1 Envs derived from 
brain or immune tissue of patients with or without neu-
roAIDS were unable to mediate infection of cells express-
ing CCR5 but not CD4. Collectively, these Envs were sig-
nificantly less able to mediate CD4-independent infection 
compared to the control SHIV Envs, which varied from low 
to high CD4 independence (p < 0.0001).
Mac‑tropic HIV‑1 Envs from neuroAIDS do not evolve 
a high‑affinity gp120:CCR5 interaction
For HIV or SIV Envs to trigger entry into  CCR5+ cells in the 
absence of CD4, it is likely that a high-affinity Env:CCR5 
interaction would need to evolve [25]. We next evaluated 
whether mac-tropic R5 Envs from brain tissue of neuroAIDS 
patients had evolved an enhanced binding affinity for CCR5 
that might facilitate CD4-independent infection via CCR5. 
For this experiment, soluble gp120s were prepared from a 
panel consisting of mac-tropic and non-mac-tropic R5 Env 
pairs derived from six neuroAIDS subjects, including five 
highly mac-tropic, brain-derived Envs (Table 1, Fig. 2). This 
panel included additional Envs derived from patients NA20, 
NA420, P1114 and JR, subjects that have been described in 
detail previously [39, 40]. They were among the first small 
group of Envs that we tested previously for CD4 independ-
ence with negative results [39].
Env binding to CCR5 was tested by measuring soluble 
gp120 attachment to CCR5 expressed on Cf2Th/CCR5 
cells [28]. Binding was tested in the absence and presence 
of sCD4. Bound gp120 or gp120/sCD4 was then detected 
using a pool of HIV-1+ sera and an anti-human IgG-FITC 
with staining measured by flow cytometry (Materials and 
methods).
Binding of several non-mac-tropic and mac-tropic gp120s 
to CCR5 was detected in the absence of sCD4. This binding 
was variable, with each of the non-mac-tropic gp120s bind-
ing CCR5 significantly more efficiently (p = 0.031) than the 
mac-tropic gp120s from the same subjects (Fig. 2A).
For all gp120s tested, sCD4 greatly enhanced gp120 
binding to CCR5, as expected (Fig. 2B), with non-mac-
tropic gp120s maintaining higher CCR5 binding capac-
ity compared to their counterpart mac-tropic gp120s for 
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the three subjects studied, although this was not signifi-
cant. Finally, the presence of 5 µg of maraviroc per ml 
blocked LN8 and LN8/sCD4 complexes from binding 
 CCR5+ Cf2Th/CCR5 cells, while 5 µg of CXCR4-specific 
AMD3100 per ml had no effect. This last observation con-
firms that the binding was CCR5 specific (Fig. 2B).
In summary, gp120s derived from immune tissue of 
neuroAIDS subjects universally maintain strong binding 
for CCR5, while gp120s from brain are more variable, 
with several binding significantly less efficiently.
Compartmentalization of mac‑tropic R5 Envs 
from brain tissue of AIDS patients
We investigated the relationship between macrophage 
tropism and population diversity of env sequences from 
brain and immune tissue of 13  HIV+ subjects with or 
without neurological complications. A phylogenetic tree 
was plotted that included representative sequences from 
all individuals studied (Fig. 3). The average evolution-
ary divergence estimate was 0.102 (S.E. = 0.009). Env 
sequences from each individual segregated separately, 
Fig. 1  No detection of CD4-independent infection by HIV-1  Env+ 
pseudoviruses carrying Envs from brain and immune tissue of AIDS 
patients. (A) Pseudoviruses carrying HIV-1 Envs derived from brain 
frontal lobe (FL), spleen (SP), or lymph node (LN) tissues of subjects 
with neuroAIDS were titrated for infection of CD4-negative Cf2Th/
CCR5 cells, primary macrophages, and HeLa TZM-bl cells. No sig-
nificant infection of Cf2Th/CCR5 cells was detected for any  Env+ 
pseudovirus tested, despite high levels of infectivity detected for mac-
rophages and HeLa TZM-bl cells. In contrast, three different SHIV 
Envs derived from brain tissue of an SHIV-infected macaque medi-
ated significant CD4-independent infection of Cf2Th/CCR5 cells as 
well as substantial infection of macrophages and HeLa TZM-bl cells 
(right 3 bars). (B). Pseudoviruses carrying HIV-1 Envs derived from 
brain frontal lobe or spleen tissues derived from subjects without or 
with only minor neurological issues failed to mediate infection of 
Cf2Th/CCR5 cells. Most Envs derived from these subjects were not 
mac-tropic despite conferred high levels of infection for HeLa TZM-
bl cells
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which is consistent with their different origins and indi-
cate that a diverse clade B env population was studied.
Our studies also confirm that there is strong com-
partmentalization of highly mac-tropic R5 HIV variants 
that predominate in brain tissue of individuals with neu-
roAIDS. In contrast, Envs from immune tissues mostly 
varied in mac-tropism from background to modest, but 
in a minority of Envs, mac-tropism was highly efficient 
[20]. Fewer mac-tropic Envs were present in brain tis-
sue of patients without neurological complications and 
formed phylogenetic clusters distinct from those of most 
non-mac-tropic Envs from the immune tissue or brain 
[21]. More-detailed amino acid sequence analysis was 
published previously [20, 21].
Discussion
Previously, we reported that CD4 independence was a 
property that is associated more with Envs of HIV-2 and 
SIV isolates than with those of HIV-1 [8, 45]. However, 
a more recent report from Cheng-Mayer and coworkers 
group described CD4-independent, mac-tropic SHIV vari-
ants that are present in brain tissue of macaques with neu-
rological disease [62]. Since SHIV env genes are derived 
from HIV-1, we were motivated to investigate whether 
any of a large panel HIV-1 R5 Envs derived from AIDS 
patients could also infect CCR5-expressing cells without 
CD4. These Envs were derived mainly from brain and 
Fig. 2  Mac-tropic and non-mac-tropic soluble gp120 binding to cell-
surface CCR5. Soluble gp120s from highly mac-tropic and non-mac-
tropic R5 Envs from subjects JR, NA20, NA420, 6568, 7766 and 
P1114 were investigated for binding to CCR5. (A and B) Soluble 
gp120 binding to canine Cf2Th/CCR5 cells in the absence (A) and 
presence of sCD4 (B). 10 μg of gp120 per ml with or without sCD4 
(5 μg/ml) was bound to Cf2Th/CCR5 and detected by flow cytometry 
using a mixture of HIV-1+ human sera (1:2,500) and an anti-human 
Ig FITC conjugate. Soluble CD4 enhanced binding as expected 
(B). Soluble gp120 from non-mac-tropic Envs bound CCR5 in the 
absence of CD4 more efficiently than gp120s from mac-tropic Envs 
(p = 0.031), and sometimes more efficiently in the presence of sCD4 
(not significant). (C) NA20 LN8 binding to CCR5 was inhibited 
by the CCR5-specific antagonist maraviroc, but not by the CXCR4 
antagonist AMD3100, as expected
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immune tissue from subjects infected with HIV-1 of clade 
B, and without neurological disease, as we have described 
previously [20, 21]. Here, no evidence of CD4-independ-
ent infection was detected for  Env+ pseudoviruses carrying 
any of the more than 100 HIV-1 Envs tested.
Previous studies by our group and others have indi-
cated that HIV-1 mac-tropism in brain tissue involves the 
evolution of high-affinity Env:CD4 interactions so that 
small amounts of CD4 on macrophages can be exploited 
to trigger viral entry [15, 37, 41, 43]. It is unclear whether 
similar changes occur in SIV or HIV-2. However, CD4 
independence is indicative of an increase in the exposure 
for the coreceptor binding site on Env, perhaps combined 
with enhanced Env:CCR5 affinity. This capacity to infect 
 coreceptor+ cells without CD4 will obviously help variants 
to infect macrophages that express only low amounts of 
CD4 [2, 30, 35] and could explain infection of astrocytes, 
which is sometimes detected in late-stage neurological 
disease [1, 7, 44, 47, 50, 52, 56]. Thus, it is likely that 
low amounts of CD4 on the cell surface of macrophages 
may greatly enhance infection by CD4-independent vari-
ants by augmenting virus binding or acting cooperatively 
to trigger conformational changes leading to fusion [8]. 
Together, these different observations support two evo-
lutionary routes to mac-tropism, one involving enhanced 
Env:CD4 interactions for HIV-1 and the second involving 
enhanced Env:CCR5 interactions for SIV and SHIV.
An earlier report describing CD4-independent SHIVs 
(which carry HIV-1 clade-C-derived Envs) in macaque 
brain [62] contrasts with the presence of CD4-dependent 
Envs in the brain of HIV-1 clade  B+ subjects described 
here. Why do HIV-1 Envs evolve CD4 independence in the 
context of SHIV and macaques but remain CD4 dependent 
with an enhanced Env:CD4 affinity in the context of HIV-1 
and humans? One possibility is that the macaque mod-
els of SIV or SHIV neurological disease occur in animals 
that are immunosuppressed or are rapid progressor animals 
where neurological disease progresses before a potent 
immune response can be elicited. For example, the neu-
roAIDS model used by Cheng-Mayer’s group occurred in 
rapid-progressor macaques with poor antibody responses 
[62]. SIVmac models of neurological disease also often 
require immune modulation, e.g., CD8 cell depletion [4, 
59]. These conditions may favor the evolution of variants 
with more open Env trimers that are capable of interact-
ing directly with coreceptors. Such variants are likely to 
be highly neutralization sensitive [55] and potentially 
selected against in HIV-1-infected humans, where the neu-
tralizing antibody response is reasonably robust [32, 33].
Fig. 3  Mac-tropic R5 Envs from 
brain tissue of AIDS patients 
cluster together. A phylogenetic 
tree was constructed by the 
maximum-likelihood method, 
and macrophage infectivities 
of HIV-1 envelope nucleotide 
sequences from brain (closed 
circles) and immune tissue/
CSF (open circles) of  HIV+ 
individuals are shown. Numbers 
at branch points represent boot-
strap values (≥70%)
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It should also be noted that it was necessary for patho-
genic SHIVs to go through serial passage in macaques to 
select for neuropathogenic viral forms [4, 59, 62]. This adap-
tation results in the selection of variants that are able to 
efficiently use macaque CD4, where changes in the trimeric 
Env quartenary structure have been described [5]. These 
(and other changes) may predispose SHIV Envs to evolve 
CD4 independence.
CD4-independent infection of  CCR5+ cells may involve 
variants that have evolved a higher Env:CCR5 affinity. We 
evaluated whether brain or mac-tropic HIV-1 Envs have a 
higher affinity for CCR5 that predisposes them to CD4 inde-
pendence even though they were CD4-dependent. Several 
previous studies have indicated that enhanced or altered 
Env:CCR5 interactions are associated with HIV-1 R5 mac-
rophage tropism [25, 46, 48, 51]. For example, Salemi et al. 
reported that mac-tropic Envs were more dependent on 
determinants in the CCR5 N-terminus than non-mac-tropic 
Envs [48]. The roles of different CCR5 residues or domains 
in Env binding were not tested here. However, we did previ-
ously report that R5 Env sensitivity to CCR5 antagonists 
was variable but did not correlate with macrophage tropism 
[37, 41]. Here, we show that R5 gp120s vary in their ability 
to bind CCR5, with the non-mac-tropic gp120s conferring 
the most efficient binding, while several gp120s from highly 
mac-tropic Envs bound less efficiently. These data are not 
inconsistent with differences in the interactions of Env with 
the N-terminus of CCR5 as reported by Salimi et al. [48]. 
However, they do not indicate that mac-tropic R5 Envs con-
sistently evolve an enhanced or highly efficient CCR5 inter-
action to facilitate macrophage infection.
It was not possible to establish an Env:CCR5 binding 
assay using trimeric Envs expressed on 293T cells, since 
there are no suitable forms of soluble CCR5 to use in such 
an assay. Highly purified forms of CCR5 have been used 
to produce high-resolution structures of CCR5 [54], but 
these contain CCR5 complexed with maraviroc, a CCR5 
antagonist that prevents Env:CCR5 binding. It is also impor-
tant to note that soluble gp120 produced from 293T cells 
may contain unnatural dimers, which have been reported 
to affect estimates of gp120:CD4 affinity, although effects 
on Env:CCR5 interactions have not been reported [10]. The 
gp120 preparations used here contained small amounts of 
dimers, although some had somewhat larger amounts (not 
shown). The presence of dimers in the gp120 preparation did 
not correlate with the extent of CCR5 binding, mac-tropism 
or tissue origin of Envs. However, we cannot state for certain 
that the presence of dimers in some gp120 preparations did 
not have some influence on gp120:CCR5 binding.
Previous studies by our group and others have found a 
strong compartmentalization of highly mac-tropic R5 HIV 
variants in brain tissue in individuals with neuroAIDS. In 
contrast, only a few mac-tropic Envs were detected in brain 
tissue of patients without neurological complications but 
formed phylogenetic clusters that were distinct from those 
of most non-mac-tropic Envs. We have also reported that 
highly mac-tropic gp120 variants carrying a lower charge 
were nearly universal in the brain when compared to Envs 
from immune tissue of neuroAIDS patients. However, only 
one patient with normal neurology carried brain Envs with 
a significantly lower charge than those in immune tissue, 
and it is possible that low Env charge is associated with 
the development of neurovirulence. A relationship between 
increased neuropathology and CD4 independence in an 
SHIV-induced encephalitis model has been described pre-
viously [62]. However, the correlation between the overall 
positive charge and variation of CD4 independence in SHIV 
Envs has not yet been studied.
In summary, in this study we investigated a diverse HIV-1 
clade B Env population to assess whether highly mac-tropic 
HIV-1 Envs derived from brain tissue have evolved an 
enhanced affinity for CCR5 and/or are able to infect cells 
without CD4. No evidence of such CD4 independence was 
detected. We conclude that mac-tropism in SIV and SHIV 
models of neurotropism evolves via mechanisms that differ 
from those of HIV-1 clade B in humans.
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